SAIR is an open-sourced dataset and is publicly available for free under a permissive CC BY 4.0 license, making it immediately actionable for commercial and non-commercial R&D pipelines. More than just a dataset, SAIR is a strategic asset that bridges the long-standing data gap in AI-powered drug design. It empowers pharmaceutical, biotech, and tech‑bio leaders to accelerate R&D, expand target horizons, and supercharge AI models – moving more of the costly, lengthy drug design and optimization from the wet lab to in silico. This means shorter hit‑to‑lead timelines, more efficient lead optimization, fewer dead‑end projects, and a more predictable path from initial idea to clinical candidate.

AI and computer-aided design have great potential in dramatically accelerating the development of new drugs. For decades, scientists have dreamed about AI that could identify or design a potent, non-toxic, and efficacious compound from a prompt describing the disease pathway, practically compressing years of drug R&D into a few minutes on a computer. However, this vision is bottlenecked by AI's ability to predict critical drug properties like potency, toxicity, etc., based solely on its molecular structure.

Furthermore, traditional structure‑based discovery is often slowed early by the determination of reliable 3D structures. Three‑dimensional molecular structure dictates a molecule’s functionality, dynamics and interactions, which is especially important when a potential drug candidate is expected to bind to a human protein target.

Experimental methods, such as X-ray crystallography and cryo-EM, require extensive time and investment, and many promising disease targets still lack experimentally validated structural information.

Source link